Molly Carr - 31 Jul 2026 Form 4 Insider Report for iBio, Inc. (IBIO)

Reporting relationship: Chief Medical Officer
Issuer ticker: IBIO
Reported as of: 31 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 16:01:36 UTC
Source filing: View source filing
Reporting owner signature: /s/ Marc Banjak, Attorney-in-Fact

Key filing fact

Molly Carr filed Form 4 for iBio, Inc. (IBIO) on 04 Aug 2026.

Key facts

This page summarizes Molly Carr's Form 4 filing for iBio, Inc. (IBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 16:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002147544 Primary reporting owner

Carr Molly

Relationship: Chief Medical Officer
Address: C/O IBIO, INC., 11750 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO
Signature: /s/ Marc Banjak, Attorney-in-Fact
Signature date: 04 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBIO transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +430,000
Change %
Price: $0.000000^*
Shares after: 430,000
Date: 31 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 430,000
Exercise price: $1.40
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Stock option granted as an inducement award to the Reporting Person that was granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026 (the "Grant Date").

Footnote F2

Vesting 25% on the one-year anniversary of the Grant Date, with an additional 6.25% vesting every three months thereafter, provided the Reporting Person remains employed by iBio, Inc. through each applicable vesting date.